Search

Your search keyword '"Marty, Francisco"' showing total 268 results
Start Over Author "Marty, Francisco" Search Limiters Peer Reviewed
268 results on '"Marty, Francisco"'

8. BK virus–specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation

Author

Espada, Eduardo, Cheng, Matthew P., Kim, Haesook T., Woolley, Ann E., Avigan, Jason I., Forcade, Edouard, Soares, Maria V.D., Lacerda, João F., Nikiforow, Sarah, Gooptu, Mahasweta, Romee, Rizwan, Alyea, Edwin P., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Koreth, John, Antin, Joseph H., Soiffer, Robert J., Marty, Francisco M., and Ritz, Jerome

Published
2020
Full Text
View/download PDF

15. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

Author

Marty, Francisco M, Ostrosky-Zeichner, Luis, Cornely, Oliver A, Mullane, Kathleen M, Perfect, John R, Thompson, George R, III, Alangaden, George J, Brown, Janice M, Fredricks, David N, Heinz, Werner J, Herbrecht, Raoul, Klimko, Nikolai, Klyasova, Galina, Maertens, Johan A, Melinkeri, Sameer R, Oren, Ilana, Pappas, Peter G, Ráčil, Zdeněk, Rahav, Galia, Santos, Rodrigo, Schwartz, Stefan, Vehreschild, J Janne, Young, Jo-Anne H, Chetchotisakd, Ploenchan, Jaruratanasirikul, Sutep, Kanj, Souha S, Engelhardt, Marc, Kaufhold, Achim, Ito, Masanori, Lee, Misun, Sasse, Carolyn, Maher, Rochelle M, Zeiher, Bernhardt, and Vehreschild, Maria J G T

Published
2016
Full Text
View/download PDF

17. Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors

Author

Young, Jo-Anne H., Logan, Brent R., Wu, Juan, Wingard, John R., Weisdorf, Daniel J., Mudrick, Cathryn, Knust, Kristin, Horowitz, Mary M., Confer, Dennis L., Dubberke, Erik R., Pergam, Steven A., Marty, Francisco M., Strasfeld, Lynne M., Brown, Janice (Wes) M., Langston, Amelia A., Schuster, Mindy G., Kaul, Daniel R., Martin, Stanley I., and Anasetti, Claudio

Published
2016
Full Text
View/download PDF

24. Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double–Blind Trial.

Author

Somersan-Karakaya, Selin, Mylonakis, Eleftherios, Mou, Jenni, Oviedo-Orta, Ernesto, O'Brien, Meagan P, Casullo, Veronica Mas, Mahmood, Adnan, Hooper, Andrea T, Hussein, Mohamed, Ali, Shazia, Marty, Francisco M, Forleo-Neto, Eduardo, Bhore, Rafia, Hamilton, Jennifer D, Herman, Gary A, Hirshberg, Boaz, and Weinreich, David M

Abstract

Background Individuals who are immunocompromised (IC) are at high risk for severe coronavirus disease 2019 (COVID-19). Methods Post hoc analyses of a double-blind trial conducted prior to Omicron (June 2020–April 2021), in hospitalized patients with COVID-19 assessed viral load, clinical outcomes, and safety of casirivimab plus imdevimab (CAS + IMD) versus placebo in IC versus overall study patients. Results Ninety-nine of 1940 (5.1%) patients were IC. IC versus overall patients were more frequently seronegative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies (68.7% vs 41.2%) and had higher median baseline viral loads (7.21 vs 6.32 log10 copies/mL). On placebo, IC versus overall patients had slower viral load declines. CAS + IMD reduced viral load in IC and overall patients; least-squares mean difference versus placebo in time-weighted average change from baseline viral load at day 7 was −0.69 (95% confidence interval [CI], −1.25 to −.14) log10 copies/mL for IC patients and −0.31 (95% CI, −.42 to −.20) log10 copies/mL for overall patients. For IC patients, the cumulative incidence of death or mechanical ventilation at day 29 was lower with CAS + IMD (11.0%) versus placebo (17.2%), consistent with overall patients (15.7% CAS + IMD vs 18.3% placebo). IC and overall patients receiving CAS + IMD exhibited similar rates of treatment-emergent adverse events (30.4% and 26.6%, respectively), grade ≥2 hypersensitivity or infusion-related reactions (1.4% and 2.5%), and deaths (8.7% and 12.2%). Conclusions IC patients were more likely to exhibit high viral loads and be seronegative at baseline. For susceptible SARS-CoV-2 variants, CAS + IMD reduced viral load and resulted in fewer death or mechanical ventilation events in IC and overall study patients. There were no new safety findings among IC patients. Clinical Trials Registration. NCT04426695. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Persistent and Relapsing Babesiosis in Immunocompromised Patients

Author

Krause, Peter J., Gewurz, Benjamin E., Hill, David, Marty, Francisco M., Vannier, Edouard, Foppa, Ivo M., Furman, Richard R., Neuhaus, Ellen, Skowron, Gail, Gupta, Shaili, McCalla, Carlo, Pesanti, Edward L., Young, Mary, Heiman, Donald, Hsue, Gunther, Gelfand, Jeffrey A., Wormser, Gary P., Dickason, John, Bia, Frank J., Hartman, Barry, Telford, Sam R., Christianson, Diane, Dardick, Kenneth, Coleman, Morton, Girotto, Jennifer E., and Spielman, Andrew

Published
2008
Full Text
View/download PDF

34. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

Author

Marty, Francisco M, Ljungman, Per, Papanicolaou, Genovefa A, Winston, Drew J, Chemaly, Roy F, Strasfeld, Lynne, Young, Jo-Anne H, Rodriguez, Tulio, Maertens, Johan, Schmitt, Michael, Einsele, Hermann, Ferrant, Augustin, Lipton, Jeffrey H, Villano, Stephen A, Chen, Hongzi, and Boeckh, Michael

Published
2011
Full Text
View/download PDF

41. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.

Author

Avery, Robin K, Alain, Sophie, Alexander, Barbara D, Blumberg, Emily A, Chemaly, Roy F, Cordonnier, Catherine, Duarte, Rafael F, Florescu, Diana F, Kamar, Nassim, Kumar, Deepali, Maertens, Johan, Marty, Francisco M, Papanicolaou, Genovefa A, Silveira, Fernanda P, Witzke, Oliver, Wu, Jingyang, Sundberg, Aimee K, Fournier, Martha, and Investigators, SOLSTICE Trial

Subjects
CONFIDENCE intervals, CYTOMEGALOVIRUS diseases, ANTIVIRAL agents, PATIENTS, TREATMENT effectiveness, RANDOMIZED controlled trials, PRE-tests & post-tests, COMPARATIVE studies, DESCRIPTIVE statistics, DRUG resistance in microorganisms, STATISTICAL sampling, TRANSPLANTATION of organs, tissues, etc.
Abstract

Background Therapies for refractory cytomegalovirus infections (with or without resistance [R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti-cytomegalovirus activity through the inhibition of UL97 protein kinase. Methods In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomized 2:1 to maribavir 400 mg twice daily or investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir) for 8 weeks, with 12 weeks of follow-up. The primary endpoint was confirmed cytomegalovirus clearance at end of week 8. The key secondary endpoint was achievement of cytomegalovirus clearance and symptom control at end of week 8, maintained through week 16. Results 352 patients were randomized (235 maribavir; 117 IAT). Significantly more patients in the maribavir versus IAT group achieved the primary endpoint (55.7% vs 23.9%; adjusted difference [95% confidence interval (CI)]: 32.8% [22.80–42.74]; P  < .001) and key secondary endpoint (18.7% vs 10.3%; adjusted difference [95% CI]: 9.5% [2.02–16.88]; P  = .01). Rates of treatment-emergent adverse events (TEAEs) were similar between groups (maribavir, 97.4%; IAT, 91.4%). Maribavir was associated with less acute kidney injury versus foscarnet (8.5% vs 21.3%) and neutropenia versus valganciclovir/ganciclovir (9.4% vs 33.9%). Fewer patients discontinued treatment due to TEAEs with maribavir (13.2%) than IAT (31.9%). One patient per group had fatal treatment-related TEAEs. Conclusions Maribavir was superior to IAT for cytomegalovirus viremia clearance and viremia clearance plus symptom control maintained post-therapy in transplant recipients with R/R cytomegalovirus. Maribavir had fewer treatment discontinuations due to TEAEs than IAT. Clinical Trials Registration. NCT02931539 (SOLSTICE). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Economic and clinical burden associated with respiratory viral infections after allogeneic hematopoietic cell transplant in the United States.

Author

Ison, Michael G., Marty, Francisco M., Chao, Nelson, Moon, Seung Hyun, Zhang, Zhiji, and Chandak, Aastha

Subjects
*INFLUENZA, *VIRUS diseases, *HUMAN metapneumovirus infection, *RESPIRATORY infections, *PARAINFLUENZA viruses, *RESPIRATORY syncytial virus, *GRAFT versus host disease
Abstract

Background: Allogeneic hematopoietic cell transplant (allo‐HCT) recipients are at increased risk for respiratory viral infections (RVIs), which invoke substantial morbidity and mortality. Limited effective antiviral options and drug resistance often hamper successful RVI treatment, creating additional burden for patients and the health care system. Methods: Using an open‐source health care claims database, we examined differences in clinical outcomes, health resource utilization, and total reimbursements during the 1‐year period following allo‐HCT in patients with and without any RVI infection (respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus). RVIs were diagnosed at any time ≤1 year after allo‐HCT and identified by International Classification of Disease codes. Analyses were stratified by the presence or absence of acute or chronic graft‐versus‐host disease (GVHD). Results: The study included 13 363 allo‐HCT patients, 1368 (10.2%) of whom had a diagnostic code for any RVI. A higher proportion of patients with any RVI had pneumonia ≤1 year after allo‐HCT compared to patients without any RVI, with or without GVHD. Patients with any RVI had higher all‐cause mortality risk, longer length of post‐allo‐HCT hospital stay, higher readmission rate, and higher number of hospital days after allo‐HCT compared to patients without the infection (all p <.05). Total unadjusted median reimbursements were higher for those with any RVI and each specific RVI assessed than those without the specific infection, with or without GVHD. Conclusion: Allo‐HCT patients with RVIs had significantly worse clinical outcomes and increased health resource utilization and reimbursements during the year following allo‐HCT, with or without GVHD. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.

Author

Chen, Evan C., Liu, Yiwen, Harris, Courtney E., Winer, Eric S., Wadleigh, Martha, Lane, Andrew A., Vedula, Rahul S., Lindsley, R. Coleman, Copson, Kevin M., Charles, Anne, Marty, Francisco, Neuberg, Donna, DeAngelo, Daniel J., Stone, Richard M., Luskin, Marlise R., Issa, Nicolas C., and Garcia, Jacqueline S.

Subjects
VENETOCLAX, ACUTE myeloid leukemia, MYCOSES, PREVENTIVE medicine, DIAGNOSIS
Abstract

Antifungal prophylaxis (AFP) is recommended for acute myeloid leukemia (AML) patients receiving the combination of venetoclax (VEN) and a hypomethylating agent (HMA), but the benefit of this practice is unclear. We identified 131 patients with newly diagnosed AML who received frontline VEN/HMA and evaluated the use of AFP and its association with invasive fungal infections (IFIs) and AML outcomes. Seventeen percent of our patients received AFP at any time. Overall incidence of any IFI ('possible,' 'probable,' or 'proven' infection, as defined by the European Mycoses Study Group) was 13%, and the incidence did not differ based on AFP use (p=.74). Median overall survival did not differ based on AFP use or lack thereof (8.1 vs. 12.5 months, respectively; p=.14). Our findings suggest that, at an institution where the incidence of fungal infections is low, there does not appear to be a role for AFP in newly diagnosed AML patients receiving VEN/HMA. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. Relationship Between Antibiotic Agent and Mortality in Patients With Febrile Neutropenia due to Staphylococcal Bloodstream Infection: A Multicenter Cohort Study.

Author

Aleissa, Muneerah M, Gonzalez-Bocco, Isabel H, Zekery-Saad, Sara, Kubiak, David W, Zhang, Eric M, Signorelli, Jessie, Hammond, Sarah P, Mohareb, Amir M, Luskin, Marlise R, Manne-Goehler, Jennifer, and Marty, Francisco M

Subjects
STAPHYLOCOCCAL diseases, FEBRILE neutropenia, BETA lactam antibiotics, COHORT analysis, ANTIBIOTICS, CEFEPIME
Abstract

Background Methicillin-susceptible Staphylococcus aureus (MSSA) is a common cause of bloodstream infection (BSI) in patients with febrile neutropenia, but treatment practices vary, and guidelines are not clear on the optimal regimen. Methods We conducted a multicenter retrospective cohort study of MSSA BSI in febrile neutropenia. We divided patients into 3 treatment groups: (1) broad-spectrum beta-lactams (ie, piperacillin-tazobactam, cefepime, meropenem); (2) narrow-spectrum beta-lactams (ie, cefazolin, oxacillin, nafcillin); and (3) combination beta-lactams (ie, both narrow- and broad-spectrum). We used multivariable logistic regression to compare 60-day mortality and bacteremia recurrence while adjusting for potential confounders. Results We identified 889 patients with MSSA BSI, 128 of whom had neutropenia at the time of the index culture: median age 56 (interquartile range, 43–65) years and 76 (59%) male. Of those, 56 (44%) received broad-spectrum beta-lactams, 30 (23%) received narrow-spectrum beta-lactams, and 42 (33%) received combination therapy. After adjusting for covariates, including disease severity, combination therapy was associated with a significantly higher odds for 60-day all-cause mortality compared with broad spectrum beta-lactams (adjusted odds ratio [aOR], 3.39; 95% confidence interval [CI], 1.29–8.89; P  = .013) and compared with narrow spectrum beta-lactams, although the latter was not statistically significant (aOR, 3.30; 95% CI,.80–13.61; P  = .071). Conclusions Use of combination beta-lactam therapy in patients with MSSA BSI and febrile neutropenia is associated with a higher mortality compared with treatment with broad-spectrum beta-lactam after adjusting for potential confounders. Patients in this study who transitioned to narrow-spectrum beta-lactam antibiotics did not have worse clinical outcomes compared with those who continued broad-spectrum beta-lactam therapy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results